-
Angion Biomedica NASDAQ:ANGN Angion Biomedica Corp. is committed to transforming the treatment paradigm for patients suffering from acute organ injuries and fibrotic diseases for which there are no approved medicines or where existing approved medicines have limitations. Angion’s lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic currently being evaluating in a Phase 3 registration trial for delayed graft function in patients undergoing deceased donor kidney transplantation, a Phase 2 trial in cardiac-surgery associated acute kidney injury, and a Phase 2 trial in patients with COVID-19 related pneumonia at high risk for acute respiratory distress syndrome. Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1. Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor.
Location: | Website: www.angion.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
0.30%
Insider Ownership
33.03%
Institutional Own.
16.37%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ELI-002 Details Pancreatic cancer, Cancer | Phase 1 Data readout | |
ANG-3777 (HGF mimetic) Details Acute respiratory distress syndrome | Failed Discontinued | |
ANG-3070 (TKI) Details Focal segmental glomerulosclerosis, IgA nephropathy | Failed Discontinued | |
ANG-3777 (HGF mimetic) Details Acute Kidney Injury | Failed Discontinued | |
ANG-3777 (HGF mimetic) Details Acute Kidney Injury | Failed Discontinued |